Valiant Laboratories Limited

NSEI:VALIANTLAB Stock Report

Market Cap: ₹4.8b

Valiant Laboratories Valuation

Is VALIANTLAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VALIANTLAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VALIANTLAB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VALIANTLAB's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for VALIANTLAB?

Key metric: As VALIANTLAB is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for VALIANTLAB. This is calculated by dividing VALIANTLAB's market cap by their current revenue.
What is VALIANTLAB's PS Ratio?
PS Ratio4.3x
Sales₹1.11b
Market Cap₹4.82b

Price to Sales Ratio vs Peers

How does VALIANTLAB's PS Ratio compare to its peers?

The above table shows the PS ratio for VALIANTLAB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.6x
524500 Kilitch Drugs (India)
3.1xn/a₹5.0b
ACCENTMIC Accent Microcell
1.9xn/a₹5.0b
541400 ZIM Laboratories
1.3xn/a₹5.1b
LYKALABS Lyka Labs
4.1xn/a₹5.1b
VALIANTLAB Valiant Laboratories
4.4xn/a₹4.8b

Price-To-Sales vs Peers: VALIANTLAB is expensive based on its Price-To-Sales Ratio (4.4x) compared to the peer average (2.6x).


Price to Sales Ratio vs Industry

How does VALIANTLAB's PS Ratio compare vs other companies in the IN Pharmaceuticals Industry?

13 CompaniesPrice / SalesEstimated GrowthMarket Cap
NECLIFE Nectar Lifesciences
0.4xn/aUS$89.20m
539561 Remedium Lifecare
0.07xn/aUS$28.41m
532637 Mangalam Drugs & Organics
0.5xn/aUS$20.07m
524412 Aarey Drugs & Pharmaceuticals
0.3xn/aUS$19.22m
VALIANTLAB 4.3xIndustry Avg. 3.1xNo. of Companies20PS02.44.87.29.612+
13 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: VALIANTLAB is expensive based on its Price-To-Sales Ratio (4.4x) compared to the Indian Pharmaceuticals industry average (3.1x).


Price to Sales Ratio vs Fair Ratio

What is VALIANTLAB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VALIANTLAB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate VALIANTLAB's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies